Pelthos Therapeutics Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Pelthos Therapeutics Inc. (PTHS) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $23.01 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-13
- Pelthos Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $23.01.
- Pelthos Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $0.00.
- Pelthos Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $13.68, a 8.74% increase from fiscal 2024.
- Pelthos Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $12.58, a 44.53% decline from fiscal 2023.
- Pelthos Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $22.68.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $23.01 10-Q · filed 2026-08-13 | ||||||
| 2026-03-31 | $23.01 10-Q/A · filed 2026-08-13 | ||||||
| 2025-12-31 | $13.68 10-K · filed 2026-03-19 | ||||||
| 2025-09-30 | $13.54 10-Q · filed 2025-11-13 | ||||||
| 2025-06-30 | $13.50 10-Q · filed 2026-08-13 | ||||||
| 2025-03-31 | $0.00 10-Q/A · filed 2026-08-13 | ||||||
| 2024-12-31 | $12.58 10-K · filed 2026-03-19 | $1.26 10-K · filed 2025-03-27 | |||||
| 2024-09-30 | $13.00 10-Q · filed 2025-11-13 | $1.30 10-Q · filed 2024-11-13 | |||||
| 2024-06-30 | $13.00 10-Q · filed 2025-08-13 | $1.30 10-Q · filed 2024-08-13 | |||||
| 2023-12-31 | $22.68 10-K · filed 2025-03-27 | ||||||
| 2023-09-30 | $22.68 10-Q · filed 2024-11-13 | ||||||
| 2023-06-30 | $22.68 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |